In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

As medicine continues to progress toward personalized medicine, targeted therapy methodologies show promise to improve ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...

Olaparib improved invasive disease-free survival, distant disease-free survival, and overall survival in high-risk ...

These quiz questions about acute myeloid leukemia (AML) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician colleagues.

With a projected Compound Annual Growth Rate (CAGR) of $% during the forecast period (2022-2028), the US AML market is well-positioned for substantial progression, underpinned by the convergence of ...